- Home
- AMSF vs LYEL Comparison
AMSF vs LYEL Comparison
Compare AMSF & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$23.81
Company Overview
Basic Information| Metric | AMSF | LYEL |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.9M | 745.5M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMSF | LYEL |
|---|---|---|
| Price | $38.07 | $23.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $58.33 | $25.00 |
| AVG Volume (30 Days) | ★ 150.3K | 133.5K |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $309,746,000.00 | $41,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $14.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.34 | $7.65 |
| 52 Week High | $53.27 | $45.00 |
Technical Indicators
Market Signals| Indicator | AMSF | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 37.37 |
| Support Level | $37.17 | $22.75 |
| Resistance Level | $38.11 | $25.12 |
| Average True Range (ATR) | 0.85 | 2.61 |
| MACD | 0.03 | -1.41 |
| Stochastic Oscillator | 42.46 | 5.76 |
Price Performance
Historical Comparison AMSF
LYEL
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.